Penza, 29 October 2014. PenzaNews. Scientists from the Lomonosov Moscow State University (MSU) presented unique eyedrops at the conference “Topical issues of ophthalmology,” held in Penza on Wednesday, October 29.

© PenzaNewsBuy the photo

As Maxim Skulachev, leading researcher of Biology Faculty told PenzaNews agency, “Vizomitin” is the first registered product based on specific mitochondrial antioxidants called “Skulachev ions.”

“We have been working on a large project over 8 years at MSU. In fact, its goal is to counter the aging process. We came up with a fairly new approach to how the aging process works. We believe that people are poisoning themselves as they age with specific substances synthesized in the body, because, from the biological point of view, we should not live too long and too well, otherwise the evolution stops. We have developed a substance that interferes with this mechanism, that intercepts synthesized toxic forms of oxygen which we are poisoning ourselves with,” the agency interlocutor explained.

According to him, it was necessary to create an experimental medicine to test this theory, which they did.

“We started with a simpler version. We added this substance to eyedrops. In theory, they were to treat certain senile diseases. And it turned out really well,” the leading researcher of Biology faculty of Moscow State University commented.

Maxim Skulachev added that “Vizomitin” eyedrops passed a series of clinical studies, including human testing, after which they were registered by the Ministry of Health of the Russian Federation.

“They are sold in pharmacies, so we can say that Russia is the only country in the world where one can buy an anti-aging medicine, even though it works only for eyes for now. But we’re working further on. This year we are starting a new study,” the agency interlocutor said.

The research and practical conference “Topical issues of ophthalmology” brought together leading experts from different regions of Russia, who exchanged the contemporary developments.

The participants discussed the experience on the diagnosis, clinical pathology and treatment of the retina, chemotherapeutic treatment for inflammatory diseases of the anterior segment of the eye, as well as new approaches to the treatment of age-related diseases.